Arcus’s ‘Last TIGIT Standing’ Shows Phase II Survival Benefit

 
• By Andrew McConaghie
  
Arcus Biosciences
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D